65 results about "Polymorphanisini" patented technology

Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.

Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).

The invention belongs to the field of chemical pharmaceutical technology and relates to an ingavirin polymorph and its preparation method. The invention aims to provide the ingavirin polymorph in allusion to insufficiencies existing in the prior art. The invention provides ingavirin polymorphs A and B which have excellent physicochemical properties and good stability and are used in the research on in vivo study of ingavirin. Meanwhile, the invention provides a preparation method of the polymorphs A and B.

The invention relates to an anti-tumor compound, the pharmaceutical composition thereof and the application thereof, particularly an anti-tumor compound shown as the formula (I) or pharmaceutically acceptable salt thereof, solvate thereof, polymorph thereof, enantiomer thereof or racemic mixture thereof; the pharmaceutical composition thereof, the application in the preparation of antitumor drugs, and the preparation method thereof. The compounds can be used as the prodrug of Dasatinib to produce Dasatinib by enzymolysis. The compounds interact with intestinal protein transporters (such as PEPT1 or PEPT2) so that the compounds can be easily absorbed in an intestinal tract in comparison with the Dasatinib to generate higher Dasatinib bioavailability.

The present invention relates to a new polymorph of Rifaximin, designated κ, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form κ of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.

The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.

The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.

Solid polymorphic forms of sulfentrazone are described. Particularly, a new polymorphic form of sulfentrazone is described herein as sulfentrazone-1, having surprising property advantages over technical sulfentrazone. Processes for the preparation of sulfentrazone-1, herbicidal compositions comprising sulfentrazone-1, and methods of its use are described.

Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific weight ratios of the forms.

Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.

The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form γ and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form γ with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.

The invention relates to the technical field of chemical pharmacy, and discloses succinate of N-cyclopentyl-5-(2-((5- ((-4ethylpiperazin1-yl) methyl) pyridine2-yl) amino) -5-fluoropyrimidine-4-yl) -4methylthiazole -2-amine and a polymorph thereof, which are inhibitors of selective cyclin-dependent kinase 4 / 6 (CDK4 / 6). The compounds are useful in the treatment of proliferative disorders, such as cancer, as well as other diseases involving protein kinase / CDK activity.

The present invention relates to a novel indoleamine-2, 3-dioxygenase (IDO) inhibitor, a preparation method therefor, and the uses thereof. The inhibitor is a compound as represented by formula (I) or a salt, a solvate, a polymorph, an enantiomer, or a racemic mixture pharmaceutically acceptable thereto. R1 or R2 is independently selected from hydrogen, a C1-C5 alkyl group, a halogen, and a substituent group as represented by formula (II), and one of the R1 and the R2 is the substituent group as represented by formula (II). R3 is selected from an aryl group, and n=0, 1, 2, or 3. Compared with a known IDO inhibitor, the novel inhibitor has a more powerful IDO inhibitory effect, and can be used to treat diseases having a pathological feature of an IDO-mediated tryptophan metabolic pathway, for example, tumors, cancers, Alzheimer disease, autoimmune diseases, cataract, mental disorders, depression, and / or anxiety disorders. The preparation method therefor has the advantages of easy operation and a mild reaction condition, and saves the solvent and reduces pollution, thereby facilitating industrial production.

The present invention relates to process for preparation of Form I polymorph of 1-[(6- chloro-3-pyridyl) methyl]-N-nitroimidazolidin-2-ylideneamine (imidacloprid). In particular the present invention relates to process for preparation of Form I of imidacloprid containing dimer impurity <= 0.5%.

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5- alpha Ü-pyrimidin-7-ylüphenyl)acetamide (Compound (1)), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II, is also provided.